Despite these differences, evidence suggests that both IFN-γ and IL-17 are pathogenic in MS, however, different cytokines might play different roles depending on the stage of the disease (for example initiating events of the disease versus exacerbation of the disease). This evidence concerns the gene IL17A and myeloid sarcoma.